Welcome to our dedicated page for Wipro news (Ticker: $WIT), a resource for investors and traders seeking the latest updates and insights on Wipro stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Wipro's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Wipro's position in the market.
Wipro and Kognitos have collaborated to deploy GenAI-based Business Automation Solutions. Wipro Ventures participated in Kognitos' latest Series A Funding Round. The platform will automate complex business process workflows for Wipro's customers in use cases like order management, contact center, and finance and accounting services.
Rhapsody, a digital health enablement leader, announced the successful implementation of the Rhapsody Enterprise Master Person Index (EMPI) solution by NHS National Services Scotland, in partnership with Wipro UK The cloud-based solution hosted in Microsoft Azure enhances connectivity of healthcare data within NHS Scotland, providing a comprehensive view of patients' health journeys.
Wipro, a leading technology services company, will implement the Medicare Prescription Payment Plan platform for Independent Health in Western New York. The platform aims to streamline prescription payments, introducing capped monthly payments for out-of-pocket drugs starting in 2025.
